These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 29573529)

  • 1. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
    Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):1988-1993. PubMed ID: 29573529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level.
    Cho J; Doo SW; Song N; Lee M; Lee H; Kim H; Jeon JS; Noh H; Kwon SH
    Clin Pharmacol Ther; 2024 Jun; 115(6):1441-1449. PubMed ID: 38451017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
    Petrykiv SI; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2017 Oct; 19(10):1363-1370. PubMed ID: 28295959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
    Petrykiv S; Sjöström CD; Greasley PJ; Xu J; Persson F; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 May; 12(5):751-759. PubMed ID: 28302903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
    Hiramatsu T; Ito H; Okumura S; Asano Y; Iguchi D; Furuta S
    Diab Vasc Dis Res; 2020; 17(6):1479164120971220. PubMed ID: 33371732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
    Hallow KM; Boulton DW; Penland RC; Helmlinger G; Nieves EH; van Raalte DH; Heerspink HL; Greasley PJ
    J Pharmacol Exp Ther; 2020 Oct; 375(1):76-91. PubMed ID: 32764153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
    Yoshihara F; Imazu M; Hamasaki T; Anzai T; Yasuda S; Ito S; Yamamoto H; Hashimura K; Yasumura Y; Mori K; Watanabe M; Asakura M; Kitakaze M;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):183-190. PubMed ID: 29589153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
    Idzerda NMA; Stefansson BV; Pena MJ; Sjostrom DC; Wheeler DC; Heerspink HJL
    Nephrol Dial Transplant; 2020 Sep; 35(9):1570-1576. PubMed ID: 31005993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
    Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
    Gessner A; Gemeinhardt A; Bosch A; Kannenkeril D; Staerk C; Mayr A; Fromm MF; Schmieder RE; Maas R
    Cardiovasc Diabetol; 2022 Jan; 21(1):4. PubMed ID: 34991562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.